Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal

Year




On May 7, 2020, Edwards Lifesciences Corporation, a Delaware corporation (the
"Company") held its 2020 Annual Meeting of Stockholders (the "Annual Meeting"),
at which stockholders approved an amendment (the "Amendment") to the Company's
Amended and Restated Certificate of Incorporation to increase the number of
authorized shares of common stock from 350 million shares to 1.05 billion shares
for the purpose of effecting a three-for-one forward split. The Amendment became
effective immediately upon filing with the Secretary of State of the State of
Delaware on May 7, 2020. The Amendment is filed as Exhibit 3.1 to this Current
Report on Form 8-K and is incorporated herein by reference.

Item 5.07. Submission of Matters to a Vote of Security Holders




On May 7, 2020, the Company held its Annual Meeting. The final results of voting
for each matter submitted to a vote of stockholders at the Annual Meeting are as
follows:

(i) Proposal 1: All the nominees for director listed in Proposal 1 were elected

to serve until the Company's next annual meeting of stockholders and until

their respective successors are duly elected and qualified as set forth


    below:


Nominee                                  For             Against           Abstain         Broker Non-Votes

Michael A. Mussallem                  157,481,237         8,474,454        1,249,682              12,905,840
Kieran T. Gallahue                    147,398,516        19,608,737          198,120              12,905,840
Leslie S. Heisz                       166,136,448           869,369          199,556              12,905,840
William J. Link, Ph.D.                157,861,919         8,151,087        1,192,367              12,905,840
Steven R. Loranger                    164,712,949         2,285,664          206,760              12,905,840
Martha H. Marsh                       164,712,482         2,299,683          193,208              12,905,840
Ramona Sequeira                       166,609,905           379,443          216,025              12,905,840
Nicholas J. Valeriani                 164,696,291         2,281,116          227,966              12,905,840

(ii) Proposal 2: The advisory proposal regarding the Company's named executive

officer compensation was approved as set forth below:

For Against Abstain Broker Non-Votes 156,231,572 10,652,305 321,496 12,905,840

(iii) Proposal 3: The 2020 Nonemployee Directors Stock Incentive Program was

approved as set forth below:




    For        Against    Abstain   Broker Non-Votes
158,980,270   7,898,492   326,611      12,905,840

--------------------------------------------------------------------------------

(iv) Proposal 4: The amendment of the Company's Amended and Restated Certificate

of Incorporation to increase the number of authorized shares of common stock


     for the purpose of effecting a three-for-one stock split was approved as set
     forth below:


    For        Against    Abstain
178,250,404   1,712,375   148,434

(v) Proposal 5: Ratification of the appointment of PricewaterhouseCoopers LLP as

the Company's independent registered public accounting firm for the fiscal

year ending December 31, 2020 was approved as set forth below:




    For        Against    Abstain
170,659,116   9,217,670   234,427

(vi) Proposal 6: The advisory stockholder proposal regarding action by written

consent was not approved as set forth below:




   For         Against     Abstain   Broker Non-Votes
29,599,433   136,875,003   730,937      12,905,840

Item 7.01. Regulation FD Disclosure




On May 7, 2020, the Company issued a press release announcing the retirement of
Wesley von Schack from the Board of Directors, the appointment of Martha Marsh
as the new Lead Independent Director, the election of Ramona Sequeira to the
Board at the Annual Meeting and a three-for-one stock split of the outstanding
shares of the Company's common stock. A copy of the press release is attached as
Exhibit 99.1, and is incorporated herein by reference.

In accordance with General Instruction B.2 of Form 8-K, the information in this
Item 7.01, including Exhibit 99.1, shall not be deemed to be "filed" for
purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the
"Exchange Act"), or otherwise subject to the liabilities of that section, and
shall not be incorporated by reference into any registration statement or other
document filed under the Securities Act of 1933, as amended, or the Exchange
Act, except as shall be expressly set forth by specific reference in such
filing.

Item 9.01. Financial Statements and Exhibits




(d) Exhibits.


 Exhibit
   No.            Description

    3.1             Certificate of Amendment of Amended and Restated Certificate of
                  Incorporation

   99.1             Press Release dated May 7, 2020

   104            Cover Page Interactive Data File (embedded within the Inline XBRL
                  document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses